Introduction
============

Hepatocellular carcinoma (HCC) is the second and sixth most deadly malignancy occurring in men and women worldwide. [@B1] Percutaneous radiofrequency ablation (RFA) therapy, which was introduced in our country in 1999, has shown superior local tumor control efficacies and greater survival benefit and is currently well established as the standard ablative therapy for early-stage HCC. [@B2]-[@B8] Over the past decade, numerous clinical and biochemical predictors have been established in an attempt to more accurately predict clinical outcomes for HCC patients undergoing RFA and assess their survival correctly. [@B2]-[@B8]

Sarcopenia is a clinical entity that is associated with decline of skeletal muscle mass and muscle strength. [@B9]-[@B13] Sarcopenia is closely linked to aging, which is called primary sarcopenia, and it has recently drawn much caution in the clinical settings owing to its significant adverse effect on outcomes. [@B9]-[@B13] Cirrhosis can cause secondary sarcopenia due to dysfunction of protein and energy metabolism in the liver. [@B10], [@B12], [@B13] In daily clinical practice, skeletal muscle mass can be evaluated using bioimpedance analysis, dual energy X-ray absorptiometry, computed tomography (CT) and magnetic resonance imaging (MRI), which are accurate and consistent assessment modalities. [@B12]-[@B16] In the field of liver diseases, CT has been frequently used for assessing the severity of liver diseases such as liver deformity, HCC development and presence of ascites and skeletal muscle mass loss has been demonstrated to be an adverse predictor for HCC patients undergoing surgery in numerous Japanese studies. [@B12], [@B14], [@B17]-[@B19] In addition, not only muscle mass but also intramuscular adipose tissue content has been reported to be associated with clinical outcomes after liver transplantation. [@B20]

However, the effect of skeletal muscle mass on survival for HCC patients undergoing RFA therapy remains unclear. Addressing these clinical problems may be of importance. The aims of this study were therefore to examine the impact of skeletal muscle mass on survival for HCC patients undergoing percutaneous RFA therapy.

Patients and Methods
====================

Patients
--------

Between January 2007 and July 2015, a total of 182 consecutive treatment naïve HCC patients undergoing percutaneous RFA therapy with curative intent were admitted at our department and they were analyzed. In our department, indication for RFA was determined through discussion with surgeons and oncologists and in principal, percutaneous RFA therapy was recommended for HCC patients with the following characteristics as determined by radiologic findings including dynamic CT and MRI and laboratory data after sufficient informed consent: (1) patients with Child-Pugh A or Child-Pugh B (2) tumor size up to 3 cm and tumor number up to 3; (3) the absence of uncontrollable ascites; (4) no obvious tumor invasion into the portal vein or the biliary tract; (5) no extrahepatic metastases and (6) no obvious evidence of bleeding tendency. In cases with maximum tumor size \>3 cm, when the patient was ineligible for surgery or did not agree to surgery, RFA therapy was considered. In cases with Child-Pugh C, RFA was performed after full explanation for risk and benefit in RFA therapy. Follow-up observation after initial RFA included periodical blood testing, radiological assessments by ultrasonography (US), CT or MRI for detecting HCC recurrence every 3-6 months. In cases of HCC recurrence, most appropriate therapy was selected for each patient.

For patients with lower serum albumin level (\<3.5 g/dl), branched-chain amino acid (BCAA) treatment or late evening snack with BCAA enriched snacks were in consideration after sufficient evaluation of nutritional status. [@B21]-[@B25] For patients with hepatitis virus-related chronic liver injury, antiviral treatments including direct acting antivirals (DAAs), interferon (IFN)-based regimens or nucleoside analogues were also in consideration. [@B23], [@B24] Evaluation for muscle mass was conducted using pretreatment psoas muscle index (PMI, cm^2^/m^2^) on the CT images. PMI indicates sum of bilateral psoas muscle mass calculated by manual trace at the lumber three level on the CT images divided by height squared. [@B26] The primary outcome measure was overall survival (OS). We retrospectively investigated the impact of pretreatment PMI after initial RFA therapy on survival. We also investigated parameters associated with OS in the univariate and multivariate analyses. Diagnosis for HCC was as reported previously. [@B27]-[@B29]

The ethical committee meeting in our hospital approved our study protocol and this study strictly followed all regulations of the Declaration of Helsinki.

Percutaneous RFA procedure
--------------------------

Preoperative careful US examination was performed to identify the targeted nodules and to determine the access routes. In most cases, we performed RFA using a cool-tip needle (Radionics Corp., Burlington, MA, USA). RFA was performed under real-time US guidance by well experienced operators for all patients. In some cases, contrast enhanced US was performed for the tumor visibility while performing RFA. In cases with poor visibility of the tip of RFA needle on US, the real-time electromagnetic virtual needle tracking system was used for guidance. [@B30] A 17-gauge, 2- or 3-cm cooled-tip electrode was inserted with caution by the intercostal or subcostal approach. The ablation time of a single ablation session in RFA was 12 min for the 3-cm electrode and 6 min for the 2-cm electrode in general. We used the artificial ascites technique to prevent collateral thermal injury when the anticipated ablated area for RFA was adjacent to a critical organ such as the hepatic flexure of the colon or the stomach. We also used this technique for ameliorating tumor visibility in cases with targeted nodule located in the hepatic dome area. [@B2] The ablated lesions were assessed by dynamic CT or MRI 1 and 8 weeks after RFA. Complete ablation of targeted nodule was defined as hypoattenuation of the ablated area including the surrounding liver parenchyma. Complete ablation was confirmed on radiologic findings for all analyzed subjects. No RFA procedure related death was observed.

Definition of recurrent HCC
---------------------------

We defined LTP as the presence of a recurrent HCC nodule adjacent to the ablated lesion after RFA using radiologic findings. HCC recurrence that occurred distantly from the ablated lesion in the same segment was defined as intrahepatic distant recurrence. [@B2], [@B29] Extrahepatic HCC recurrence was determined using chest CT scan, whole abdominal CT scan, bone scintigraphy and positron-emission tomography.

Statistical analyses
--------------------

We compared categorical parameters by Fisher\'s exact test and continuous parameters by unpaired *t*-test or Mann-Whitney *U*test as appropriate. In continuous parameters, receiver operating characteristics (ROC) curve for survival was created with the aim of selecting the optimal cut-off point that is linked to maximal sum of specificity and sensitivity and we classified them into two groups using these cut-off points, which was then considered as dichotomous variants in the analysis. Survival curves were created using the Kaplan-Meier method and compared in the log-rank test. Variables with *P* value \<0.05 in the univariate analysis were finally entered into the multivariate analysis in the logistic regression analysis or the Cox proportional hazards model as appropriate. OS was defined as the interval from the date of initial RFA therapy until death from any cause or the last follow-up visit. Recurrence free survival (RFS) was defined as the interval from the date of initial RFA therapy until the first confirmed HCC recurrence or the last follow-up date in radiological evaluation. Data are shown as the median value (range) unless otherwise mentioned. The significant threshold value was set at *P*\<0.05. Statistical analysis was performed with the JMP 11 (SAS Institute Inc., Cary, NC).

Results
=======

Baseline characteristics
------------------------

The baseline characteristics of the analyzed subjects (n=182) are presented in table [1](#T1){ref-type="table"}. They included 111 males and 71 females with median age (range) of 70 (41-93) years. The median follow-up periods were 4.28 years (range: 0.38-9.81 years). The median (range) value in PMI for male was 6.03 (1.63-9.90) cm^2^/m^2^ whereas that for female was 4.06 (1.21-7.32) cm^2^/m^2^ (*P*\<0.0001). Maximum tumor size ranged from 0.7 cm to 3.5 cm (median, 1.5cm). In 26 patients (14.3%), small ascites was found on CT images. There were 145 patients with single nodule and 37 with multiple nodules (2 or 3 nodules). As for cause of liver disease, patients were predominantly hepatitis C virus (HCV) (73.6%, 134/182). As for Child-Pugh classification, Child-Pugh A was in the majority (75.3%, 137/182).

Outcome based ROC analysis for selecting optimal cut-off point in PMI
---------------------------------------------------------------------

Using ROC analysis for survival, the optimal cut-off point for PMI was 6.31 cm^2^/m^2^in male (area under the ROC (AUC) =0.74, sensitivity=86.5%, specificity=56.8%) and 3.91 cm^2^/m^2^in female (AUC=0.76, sensitivity=72.0%, specificity=78.3%). (Fig. [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B) When these cut-off points were applied to our subjects, a total of 90 patients (49.5%) had decreased PMI (D-PMI) (63 in male and 27 in female).

Comparison of baseline characteristics in patients with D-PMI and without D-PMI
-------------------------------------------------------------------------------

As for comparison of baseline characteristics in patients with D-PMI and without D-PMI, the proportion of male in the D-PMI group was significantly higher than that in the non-D-PMI group (*P*=0.0134). Body mass index (BMI) (*P*=0.0020) and serum albumin level (*P*=0.0217) in the D-PMI group were significantly lower than those in the non-D-PMI group. Serum creatinine in the D-PMI group were significantly higher than those in the non-D-PMI group (*P*=0.0043) (Table [2](#T2){ref-type="table"}).

Multivariate analyses of factors linked to the presence of DPMM
---------------------------------------------------------------

Multivariate analyses (logistic regression analysis) using four above significant factors (i.e., gender, BMI, serum albumin and serum creatinine) revealed that gender (*P*=0.0325), BMI (*P*=0.0011) and serum albumin (*P*=0.0071) were independent factors associated with the presence of D-PMI. The Hazard ratios (HRs) and 95% confidence intervals (CIs) of these parameters are detailed in table [3](#T3){ref-type="table"}.

Cumulative OS rates for all cases and for patients with and without DPMM
------------------------------------------------------------------------

For all cases (n=182), the 1-, 3-, 5- and 7-year cumulative OS rates were 95.0%, 84.3%, 69.2% and 56.9%, respectively. (Fig. [1](#F1){ref-type="fig"}C) The 1-, 3-, 5- and 7-year cumulative OS rates were 90.0%, 74.3%, 51.5% and 33.5%, respectively, in the D-PMI group and 100%, 94.2%, 86.5% and 81.2%, respectively, in the non-D-PMI group (*P*\<0.0001) (Fig. [1](#F1){ref-type="fig"}D).

Causes for death in the D-PMI group and the non-D-PMI group
-----------------------------------------------------------

In the D-PMI group, during the observation period, 49 patients (54.4%) died. The causes for death were liver failure in 22 patients, HCC progression in 16 patients and miscellaneous causes in 11 patients. In the non-D-PMI group, during the observation period, 13 patients (14.1%) died. The causes for death were liver failure in 2 patients, HCC progression in 8 patients and miscellaneous causes in 3 patients.

Univariate and multivariate analyses of parameters contributing to OS
---------------------------------------------------------------------

Univariate analysis identified the following factors as significantly associated with OS for all cases: presence of D-PMI (*P*\<0.0001); Child-Pugh classification (*P*\<0.0001); presence of ascites (*P*\<0.0001); total bilirubin ≥1.2 mg/dl (*P*\<0.0001); serum albumin ≥3.3 g/dl (*P*=0.0014); prothrombin time ≥70.3 % (*P*=0.0018); platelet count ≥10.0 ×10^4^/mm^3^ (*P*=0.0058); serum creatinine ≥0.84 mg/dl (*P*=0.0075); C reactive protein ≥0.2 mg/dl (*P*=0.0120); total cholesterol ≥124 mg/dl (*P*=0.0017); triglyceride ≥89 mg/dl (*P*=0.0009); branched-chain amino acid to tyrosine ratio (BTR) ≥4.25 (*P*=0.0051); serum ammonia ≥24 μg/dl (*P*=0.0446); and des-γ-carboxy prothrombin (DCP) ≥34 mAU/ml (*P*=0.0003). (Table [4](#T4){ref-type="table"}) The HRs and 95% CIs calculated by using multivariate analysis for the fourteen significant variables (*P*\<0.05) in the univariate analysis are presented in table [4](#T4){ref-type="table"}. Presence of D-PMI (*P*\<0.0001), total bilirubin ≥1.2 mg/dl (*P*=0.0015) and DCP ≥34 mAU/ml (*P*=0.0089) were found to be significant predictors related to OS in the multivariate analysis.

Subgroup analysis for OS according to Child-Pugh classification
---------------------------------------------------------------

In patients with Child-Pugh A (n=137), patients in the D-PMI group (n=66) survived significantly shorter than those in the non-D-PMI group (n=71) (*P*\<0.0001) (Fig. [2](#F2){ref-type="fig"}A). Similarly, in patients with Child-Pugh B or C (n=45), patients in the D-PMI group (n=24) survived significantly shorter than those in the non-D-PMI group (n=21) (*P*=0.0001) (Fig. [2](#F2){ref-type="fig"}B).

Sustained virological response (SVR) after RFA therapy in HCV-related HCC patients
----------------------------------------------------------------------------------

During follow-up period, 31 patients with HCV-related HCC patients (10 in the D-PMI group and 21 in the non-D-PMI group) achieved SVR after RFA therapy. Twelve patients were treated with IFN-based therapies and 19 patients were treated with DAA therapies. No patients with SVR died during follow-up period. Patients with SVR survived significantly longer than those without (n=103) (*P*=0.0002) (Fig. [3](#F3){ref-type="fig"}A). In patients without SVR, patients in the D-PMI group (n=56) survived significantly shorter than those in the non-D-PMI group (n=47) (*P*\<0.0001) (Fig. [3](#F3){ref-type="fig"}B).

Cumulative LTP rate, intrahepatic distant recurrence rate and recurrence free survival
--------------------------------------------------------------------------------------

For all cases (n=182), the 1-, 3-, 5- and 7-year cumulative LTP rates were 2.8%, 9.1%, 9.1% and 9.1%, respectively (Fig. [4](#F4){ref-type="fig"}A). The 1-, 3-, 5- and 7-year cumulative intrahepatic distant recurrence rates were 13.8%, 39.5%, 51.3% and 58.4%, respectively. (Fig. [4](#F4){ref-type="fig"}B) The 1-, 3-, 5- and 7-year cumulative RFS rates were 85.1%, 53.6%, 41.5% and 34.5%, respectively. (Fig. [4](#F4){ref-type="fig"}C) The difference of cumulative RFS rates in the D-PMI and non-D-PMI groups did not reach significance. (*P*=0.5077)

Japanese reports of the effect of muscle mass evaluated by CT on clinical outcome for HCC patients
--------------------------------------------------------------------------------------------------

Japanese reports (including our current study) of the effect of muscle mass evaluated by CT on clinical outcome for HCC patients are listed in table [5](#T5){ref-type="table"}.

Discussion
==========

To the best of our knowledge, there have been few reports regarding the effect of muscle mass on survival in HCC patients treated with percutaneous RFA therapy. [@B15], [@B32] More than ten years have passed since approval for health insurance in RFA therapy for HCC patients in our country. In those years, numerous clinical evidence for RFA therapy have been accumulated. [@B2]-[@B6] However, few investigators have addressed these critical clinical issues.

In our data, patients with D-PMI survived significantly shorter than those without and it revealed to be an independent predictor with a HR of 6.867 (the highest among analyzed variables) for survival in the multivariate analysis. In addition, this is true irrespective of Child-Pugh status and in HCV-related HCC patients without SVR, similar results were obtained. These results imply the usefulness of PMI for predicting clinical outcomes in HCC patients undergoing RFA therapy. Skeletal muscle mass appears to play a crucial role in the outcomes of RFA therapy for HCC. In daily clinical practice, clinicians should be aware of skeletal muscle mass for not only HCC patients receiving surgery but also HCC patients receiving RFA therapy. [@B12], [@B14], [@B17]-[@B20] Equilibrium of muscle synthesis (anabolism) and muscle break down (catabolism) is essential to maintain skeletal muscle mass. [@B11] The insulin growth factor 1 (IGF-1) is synthesized in the liver and myocytes in response to stimulation for exercise and IGF-1 signaling pathway significantly contributes to the maintenance of the balance between muscle synthesis and muscle break down. [@B11] The impairment of these molecular pathways seen in patients with lower muscle mass may be associated with our current results. On the other hand, in terms of HCC recurrence, PMI was not a significant predictor. Tumor related factors may be essential for predicting HCC recurrence. [@B2]-[@B6]

In terms of comparison of baseline characteristics in the D-PMI group and the non-D-PMI group, gender, BMI and serum albumin were independent factors associated with the presence of D-PMI and unexpectedly aging did not reach significance despite of the fact that with the increasing age in humans, physical function begins to decline and skeletal muscle mass begins to decrease. [@B10], [@B13] One potential reason for these results is that underlying liver diseases can strongly affect the development of muscle mass decline irrespective of age. [@B9], [@B11], [@B33] As for cut-off value for PMI on CT in liver diseases, current Japanese guidelines recommend 6.36 cm^2^/m^2^for male and 3.92 cm^2^/m^2^for female. These data were calculated by below two standard deviations from the mean PMI values in a Japanese large cohort and were not based on outcome based analysis [@B12], [@B16] While in our outcome based ROC analysis, the optimal cut-off points for survival were 6.31 cm^2^/m^2^for male and 3.91 cm^2^/m^2^for female, which were quite identical to recommendations in Japanese guidelines and support the validity of current guidelines. [@B12], [@B16] In the viewpoint of outcome based data, our results are worth reporting. On the other hand, out of 49 patients who died during follow-up period in the D-PMI group, 22 patients (44.9%) died of liver failure, while in the non-D-PMI group, only 2 (15.4%) out 13 patients died of liver failure. Considering that similar baseline characteristics were observed in terms of Child-Pugh classification in the two groups (*P*=0.6078), these data may reflect the difference of underlying liver disease progression after initial RFA in these two groups.

Shiina *et al.* reported in their large cohort study (n=1170) that 5-year OS rate was 60.2%, which was lower than our data (5-year OS rate, 69.2%). [@B7] These differences may be attributed to the treatment strategies for underlying liver diseases. As described earlier, in our department, almost all patients with serum albumin level \<3.5 g/dl received BCAA treatment or late evening snack with BCAA enriched snacks after sufficient evaluation of nutritional status including muscle mass measurement or energy metabolism using indirect calorimetry. [@B34]-[@B36] Even in patients with early stage of cirrhosis, BCAA therapy was considered for patients with BTR \<4. [@B37], [@B38] Antiviral therapy was performed for all patients eligible for antiviral therapies. We have also recommended adequate exercise for cirrhotic patients with lower muscle mass. [@B39] These treatment strategies for underlying liver disease may lead to our current results.

HCV therapy has markedly improved in recent years. [@B23], [@B40]-[@B42] In our data, irrespective of the presence or absence of D-PMI, no patients with SVR died during follow-up period. In a recent study for patients with HCV related cirrhotic patients (n=165), an achievement of SVR during follow-up period was demonstrated to be the strongest favorable predictor associated with OS with a HR of more than 20. [@B43] Thus, antiviral therapies for HCV can be strongly recommended for patients eligible for these therapies for ameliorating clinical outcomes. On the other hand, in our multivariate analysis, DCP was found to be an independent predictor for OS, while AFP was not. Elevated DCP level may be associated with the malignant potential for HCC such as the development of portal vein tumor invasion, which may be linked to our current results. [@B44], [@B45]

Several limitations require to be acknowledged in this analysis. Firstly, this study was a single center retrospective observational study and parameters reflecting muscle function such as hang grip strength or intramuscular fat accumulation were not evaluated in this study. In future studies, two critical markers (i.e., muscle mass and muscle function) should be both assessed in outcome based analyses. Secondly, only 62 patients died during observation period in this study, which may not have sufficient statistical power for survival analysis, potentially creating bias. However, our study results denoted that PMI as determined by CT images had higher predictive ability for clinical outcomes in HCC patients receiving RFA therapy.

In conclusion, PMI can be useful for predicting outcomes in HCC patients undergoing percutaneous RFA therapy.

The authors would like to thank all medical staff in our hospital for data collection.
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###### 

Baseline characteristics (n=182).

  Variables                         Number or median value (range)
  --------------------------------- --------------------------------
  Age (years)                       70 (41-93)
  Gender, male / female             111 / 71
  Cause of liver diseases           
  HBV / HCV / others                12 / 134 / 36
  Child-Pugh, A / B / C             137 / 42 / 3
  Tumor number, single / multiple   145 / 37
  Maximum tumor size (cm)           1.5 (0.7-3.5)
  Body mass index (kg/m^2^)         22.5 (14.7-33.1)
  Presence of ascites, yes / no     26 / 156
  Total bilirubin (mg/dL)           0.9 (0.3-5.5)
  Serum albumin (g/dL)              3.7 (1.8-4.7)
  Prothrombin time (%)              80.9 (50.4-108.4)
  Platelet count (×10^4^/mm^3^)     10.2 (2.5-25.3)
  AST (IU/L)                        43 (16-140)
  ALT (IU/L)                        35 (10-151)
  Total cholesterol (mg/dl) †       150 (74-274)
  Triglyceride (mg/dl) ‡            89 (30-656)
  Fasting blood glucose (mg/dl)     100 (65-296)
  Serum sodium (mmol/l)             140 (131-145)
  Serum creatinine (mg/dl)          0.74 (0.38-6.60)
  C reactive protein (mg/dl)        0.1 (0-3.0)
  Serum ammonia (μg/dl) §           38 (5-149)
  BTR ¶                             4.56 (1.77-17.39)
  Alpha fetoprotein (ng/ml)         8.7 (0.6-2593)
  DCP (mAU/ml)                      26 (5-3460)

Data are expressed as number or median (range). HBV; hepatitis B virus, HCV; hepatitis C virus, AST; aspartate aminotransferase, ALT; alanine aminotransferase, BTR; branched-chain amino acid to tyrosine ratio, DCP; des-γ-carboxy prothrombin, †; missing data, n=1, ‡; missing data, n=1, §; missing data, n=1, ¶; missing data, n=4

###### 

Comparison of baseline characteristics between the D-PMI group and the non-D-PMI group.

  ---------------------------------------------------------------------------------------------------------------
  Variables                         D-PMI group (n=90)\              Non-D-PMI group (n=92)\          *P* value
                                    Number or median value (range)   Number or median value (range)   
  --------------------------------- -------------------------------- -------------------------------- -----------
  Age (years)                       71 (48-93)                       67 (41-85)                       0.2754

  Gender, male / female             63 / 27                          48 / 44                          0.0134

  Body mass index (kg/m^2^)         22.2 (14.7-33.1)                 23.3 (18.7-30.6)                 0.0020

  Tumor number, single / multiple   75 / 15                          70 / 22                          0.2703

  Maximum tumor size (cm)           1.5 (0.7-3.5)                    1.4 (0.7-3.0)                    0.1530

  Child-Pugh, A / B or C            66 / 24                          71 / 21                          0.6078

  Presence of ascites, yes / no     15 / 75                          11 / 81                          0.4024

  Total bilirubin (mg/dl)           0.9 (0.3-5.5)                    0.9 (0.4-3.4)                    0.8818

  Serum albumin (g/dl)              3.6 (1.8-4.7)                    3.7 (2.7-4.7)                    0.0217

  Prothrombin time (%)              80.4 (50.9-108.4)                81.1 (50.4-108)                  0.9769

  Platelet count (×10^4^/mm^3^)     10.0 (3.2-24.2)                  10.45 (2.5-25.3)                 0.4891

  Serum creatinine (mg/dl)          0.79 (0.38-6.6)                  0.69 (0.39-4.6)                  0.0043

  C reactive protein (mg/dl)        0.1 (0-3.0)                      0.1 (0-0.7)                      0.1161

  AST (IU/l)                        43.5 (16-140)                    42.5 (16-139)                    0.7447

  ALT (IU/l)                        34 (10-117)                      35.5 (12-151)                    0.3929

  Total cholesterol (mg/dl)         149.5 (74-274)                   152 (93-229)                     0.6436

  Triglyceride (mg/dl)              82.5 (30-656)                    96 (30-250)                      0.0698

  Fasting blood glucose (mg/dl)     100 (72-296)                     99.5 (65-229)                    0.6261

  BTR                               4.3 (1.77-17.39)                 4.62 (1.8-10.53)                 0.8375

  Serum ammonia (μg/dl)             37 (5-114)                       39 (10-149)                      0.2180

  Alpha fetoprotein (ng/ml)         8.55 (0.6-1293)                  9.4 (1.2-2593)                   0.1804

  DCP (mAU/ml)                      31 (5-2700)                      23 (7-3460)                      0.8753
  ---------------------------------------------------------------------------------------------------------------

Data are expressed as number or median (range). D-PMI; decreased psoas muscle index, AST; aspartate aminotransferase, ALT; alanine aminotransferase, BTR; branched-chain amino acid to tyrosine ratio, DCP; des-γ-carboxy prothrombin

###### 

Multivariate analyses of factors linked to the presence of D-PMI (n=182).

  Variables                           Multivariate analysis                 
  ----------------------------------- ----------------------- ------------- --------
  Gender                              2.036                   1.061-3.962   0.0325
  Body mass index (per one kg/m^2^)   1.186                   1.069-1.328   0.0011
  Serum albumin (per one g/dl)        2.388                   1.261-4.728   0.0071
  Serum creatinine (per one mg/dl)    0.680                   0.318-1.120   0.1441

D-PMI; decreased psoas muscle index, CI; confidence interval.

###### 

Univariate and multivariate analyses of factors linked to overall survival (n=182).

  Variables                                     Number          Univariate analysis   Multivariate analysis                  
  --------------------------------------------- --------------- --------------------- ----------------------- -------------- ----------
  Age ≥61 years, yes / no                       143 / 39        0.2300                                                       
  Gender, male / female                         111 / 71        0.5297                                                       
  Cause of liver disease, B / C / others        12 / 134 / 36   0.1405                                                       
  Body mass index ≥21.6 kg/m^2^, yes / no       120 / 62        0.2152                                                       
  Tumor number, single / multiple               145 / 37        0.6351                                                       
  Maximum tumor size ≥1.1 cm, yes / no          139 / 43        0.1511                                                       
  D-PMI, yes / no                               90 / 92         \<0.0001              6.867                   3.498-14.425   \<0.0001
  Child-Pugh, A / B or C                        137 / 45        \<0.0001              0.810                   0.236-2.745    0.7350
  Presence of ascites, yes / no                 26 / 156        \<0.0001              2.629                   0.972-7.457    0.0570
  Total bilirubin ≥1.2 mg/dl, yes / no          50 / 132        \<0.0001              3.083                   1.551-6.106    0.0015
  Serum albumin ≥3.3 g/dl, yes / no             137 / 45        0.0014                0.858                   0.366-1.970    0.7200
  Prothrombin time ≥70.3 %, yes / no            136 / 46        0.0018                0.826                   0.382-1.837    0.6349
  Platelet count ≥10.0 ×10^4^/mm^3^, yes / no   98 / 84         0.0058                0.859                   0.455-1.615    0.6369
  Serum creatinine ≥0.84 mg/dl, yes / no        58 / 124        0.0075                1.325                   0.731-2.386    0.3506
  Serum sodium ≥142 mmol/l, yes / no            43 / 139        0.4428                                                       
  C reactive protein ≥0.2 mg/dl, yes / no       43 / 139        0.0120                1.312                   0.677-2.443    0.4115
  AST ≥51 IU/L, yes / no                        69 / 113        0.3546                                                       
  ALT ≥36 IU/L, yes / no                        89 / 93         0.2068                                                       
  Total cholesterol ≥124 mg/dl, yes / no        139 / 42        0.0017                0.549                   0.269-1.145    0.1081
  Triglyceride ≥89 mg/dl, yes / no              92 / 89         0.0009                0.734                   0.400-1.315    0.3012
  Fasting blood glucose ≥88 mg/dl, yes / no     164 / 18        0.1095                                                       
  BTR ≥4.25, yes / no                           102 / 76        0.0051                0.981                   0.515-1.859    0.9532
  Serum ammonia ≥24 μg/dl, yes / no             149 / 32        0.0446                1.946                   0.827-5.168    0.1317
  Alpha fetoprotein ≥243 ng/ml, yes / no        15 / 167        0.0546                                                       
  DCP ≥34 mAU/ml, yes / no                      80 / 102        0.0003                2.194                   1.215-4.062    0.0089

Data are expressed as number or median (range). In each continuous parameter, cut-off point was determined by ROC analysis for survival. D-PMI; decreased psoas muscle index. AST; aspartate aminotransferase, ALT; alanine aminotransferase, BTR; branched-chain amino acid to tyrosine ratio, DCP; des-γ-carboxy prothrombin, CI; confidence interval.

###### 

Japanese reports of the effect of muscle mass evaluated by CT on clinical outcome for hepatocellular carcinoma patients.

  Author                     Year   No. of cases   HCC therapy      Evaluation method for muscle mass   Prevalence of muscle mass loss   Outcome
  -------------------------- ------ -------------- ---------------- ----------------------------------- -------------------------------- -----------------
  Our study                  2017   182            RFA              CT (L3, PMI)                        49.5%                            *P*\<0.05 (OS)
  Hiraoka, et al. \[31\]     2016   93             Sorafenib        CT (L3, PMI)                        21.5%                            *P*=0.042 (OS)
  Kamachi, et al. \[18\]     2016   92             Surgery or RFA   CT (L3, SMI)                        66.3%                            *P*\<0.05 (RFS)
  Iritani, et al. \[32\]     2015   217            Any              CT (L3, SMI)                        11.1%                            *P*\<0.05 (OS)
  Fujiwara, et al. \[15\]    2015   1257           RFA or TACE      CT (L3, SMI)                        11.1%                            *P*\<0.05 (OS)
  Hamaguchi, et al. \[20\]   2014   200            LT               CT (L3, PMI)                        44.0%                            *P*\<0.05 (OS)
  Ito, et al. \[14\]         2014   190            Surgery          CT (L3, SMI)                        40.5%                            *P*\<0.05 (OS)
  Harimoto, et al. \[17\]    2013   186            Surgery          CT (L3, SMI)                        40.3%                            *P*\<0.05 (OS)

CT; computed tomography, RFA; radiofrequency ablation, L3; the third lumber, PMI; psoas muscle index, SMI; skeletal muscle index, TACE; transcatheter arterial chemoembolization, LT; liver transplantation, OS; overall survival, RFS; recurrence free survival.
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